Mirador Capital Partners LP Sells 72,596 Shares of Pfizer Inc. (NYSE:PFE)

Mirador Capital Partners LP reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 88.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,051 shares of the biopharmaceutical company’s stock after selling 72,596 shares during the quarter. Mirador Capital Partners LP’s holdings in Pfizer were worth $251,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Chapin Davis Inc. raised its position in Pfizer by 0.8% in the first quarter. Chapin Davis Inc. now owns 58,258 shares of the biopharmaceutical company’s stock worth $1,617,000 after acquiring an additional 459 shares during the period. Oak Asset Management LLC raised its holdings in Pfizer by 39.1% in the 1st quarter. Oak Asset Management LLC now owns 24,215 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 6,809 shares during the period. Roberts Wealth Advisors LLC purchased a new position in Pfizer during the first quarter valued at $1,374,000. Barry Investment Advisors LLC grew its holdings in Pfizer by 1.1% during the first quarter. Barry Investment Advisors LLC now owns 192,573 shares of the biopharmaceutical company’s stock valued at $5,344,000 after purchasing an additional 2,123 shares during the period. Finally, SteelPeak Wealth LLC increased its position in Pfizer by 62.6% in the first quarter. SteelPeak Wealth LLC now owns 38,810 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 14,947 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Trading Up 0.9 %

PFE stock opened at $28.22 on Tuesday. The firm has a fifty day moving average price of $27.90 and a 200 day moving average price of $27.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The firm has a market cap of $159.91 billion, a PE ratio of -470.25, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. The business’s quarterly revenue was down 19.5% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.95%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.